These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 25559930)

  • 1. Enhanced QSAR models for drug-triggered inhibition of the main cardiac ion currents.
    Wiśniowska B; Mendyk A; Szlęk J; Kołaczkowski M; Polak S
    J Appl Toxicol; 2015 Sep; 35(9):1030-9. PubMed ID: 25559930
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Boulay E; Troncy E; Jacquemet V; Huang H; Pugsley MK; Downey AM; Venegas Baca R; Authier S
    Int J Toxicol; 2024; 43(4):357-367. PubMed ID: 38477622
    [No Abstract]   [Full Text] [Related]  

  • 3. Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
    Wiśniowska B; Mendyk A; Fijorek K; Glinka A; Polak S
    J Appl Toxicol; 2012 Oct; 32(10):858-66. PubMed ID: 22761000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment.
    Elkins RC; Davies MR; Brough SJ; Gavaghan DJ; Cui Y; Abi-Gerges N; Mirams GR
    J Pharmacol Toxicol Methods; 2013; 68(1):112-22. PubMed ID: 23651875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Slow delayed rectifying potassium current (IKs ) - analysis of the in vitro inhibition data and predictive model development.
    Polak S; Wiśniowska B; Glinka A; Fijorek K; Mendyk A
    J Appl Toxicol; 2013 Aug; 33(8):723-39. PubMed ID: 22334483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.
    Bottino D; Penland RC; stamps A; Traebert M; Dumotier B; Georgiva A; Helmlinger G; Lett GS
    Prog Biophys Mol Biol; 2006; 90(1-3):414-43. PubMed ID: 16321428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arrhythmic hazard map for a 3D whole-ventricle model under multiple ion channel block.
    Okada JI; Yoshinaga T; Kurokawa J; Washio T; Furukawa T; Sawada K; Sugiura S; Hisada T
    Br J Pharmacol; 2018 Sep; 175(17):3435-3452. PubMed ID: 29745425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early assessment of proarrhythmic risk of drugs using the in vitro data and single-cell-based in silico models: proof of concept.
    Abbasi M; Small BG; Patel N; Jamei M; Polak S
    Toxicol Mech Methods; 2017 Feb; 27(2):88-99. PubMed ID: 27813448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of pioglitazone on cardiac ion currents and action potential morphology in canine ventricular myocytes.
    Kistamás K; Szentandrássy N; Hegyi B; Ruzsnavszky F; Váczi K; Bárándi L; Horváth B; Szebeni A; Magyar J; Bányász T; Kecskeméti V; Nánási PP
    Eur J Pharmacol; 2013 Jun; 710(1-3):10-9. PubMed ID: 23588116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between Hodgkin-Huxley and Markov formulations of cardiac ion channels.
    Carbonell-Pascual B; Godoy E; Ferrer A; Romero L; Ferrero JM
    J Theor Biol; 2016 Jun; 399():92-102. PubMed ID: 27059892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real Patient and its Virtual Twin: Application of Quantitative Systems Toxicology Modelling in the Cardiac Safety Assessment of Citalopram.
    Patel N; Wiśniowska B; Jamei M; Polak S
    AAPS J; 2017 Nov; 20(1):6. PubMed ID: 29181593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identify drug-induced T wave morphology changes by a cell-to-electrocardiogram model and validation with clinical trial data.
    Xue J; Gao W; Chen Y; Han X
    J Electrocardiol; 2009; 42(6):534-42. PubMed ID: 19700171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic effects in the cardiovascular system: the modeller's view.
    Fink M; Noble D
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):243-9. PubMed ID: 20470255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biophysics and Molecular Biology of Cardiac Ion Channels for the Safety Pharmacologist.
    Pugsley MK; Curtis MJ; Hayes ES
    Handb Exp Pharmacol; 2015; 229():149-203. PubMed ID: 26091640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tox-database.net: a curated resource for data describing chemical triggered in vitro cardiac ion channels inhibition.
    Polak S; Wiśniowska B; Glinka A; Polak M
    BMC Pharmacol Toxicol; 2012 Aug; 13():6. PubMed ID: 22947121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apico-basal inhomogeneity in distribution of ion channels in canine and human ventricular myocardium.
    Szentadrassy N; Banyasz T; Biro T; Szabo G; Toth BI; Magyar J; Lazar J; Varro A; Kovacs L; Nanasi PP
    Cardiovasc Res; 2005 Mar; 65(4):851-60. PubMed ID: 15721865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The neuroprotective agent sipatrigine blocks multiple cardiac ion channels and causes triangulation of the ventricular action potential.
    Gao Z; Milnes JT; Choisy SC; Leach MJ; Hancox JC; James AF
    Clin Exp Pharmacol Physiol; 2005 Dec; 32(12):1088-96. PubMed ID: 16445575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patch-clamp studies of human cardiac ion channels in the evaluation of cardiac electrophysiological effects of compounds.
    Crumb WJ; Cavero I
    Curr Protoc Pharmacol; 2003 May; Chapter 10():Unit10.8. PubMed ID: 21956800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico binary classification QSAR models based on 4D-fingerprints and MOE descriptors for prediction of hERG blockage.
    Su BH; Shen MY; Esposito EX; Hopfinger AJ; Tseng YJ
    J Chem Inf Model; 2010 Jul; 50(7):1304-18. PubMed ID: 20565102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A web portal for in-silico action potential predictions.
    Williams G; Mirams GR
    J Pharmacol Toxicol Methods; 2015; 75():10-6. PubMed ID: 25963830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.